Analysis of circulating plasmatic tumor DNA of patients who progressed to the FGFR inhibitor BGJ398 enabled the identification of polyclonal secondary FGFR2 mutations as a driving mechanism of resistance in these patients.

(Goyal L et al. – Cancer Discovery, March 2017)

Read more